2,5-Dimethoxy-4-benzylamphetamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2,5-Dimethoxy-4-benzylamphetamine (DOBz or DOBN) is a serotonin 5-HT2 receptor modulator of the amphetamine and DOx families.[1][2][3] It is the DOx derivative with a benzyl ring at the 4 position.[1]
- None
| |
| Clinical data | |
|---|---|
| Other names | DOBz; DOBZ; DOBN; DOBn; 4-Benzyl-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-benzylamphetamine |
| Drug class | Serotonin 5-HT2 receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C18H23NO2 |
| Molar mass | 285.387 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug's affinities (Ki) for the human serotonin 5-HT2 receptors have been found to be 0.40 nM for the serotonin 5-HT2A receptor, 24.5 to 35.0 nM for the serotonin 5-HT2B receptor, and 1.0 nM for the serotonin 5-HT2C receptor.[1][4] Its affinities for the serotonin 5-HT2 receptors are very similar to those of DOB.[1] The drug has been assessed and found to act as a silent antagonist of the serotonin 5-HT2B receptor (Emax = 0%).[4] In rodent drug discrimination tests, DOBz neither antagonized nor generalized to the stimulus of DOM.[5][6] Higher doses produced behavioral disruption however.[5]
DOBz was first described in the scientific literature by Richard Glennon and colleagues in 1989.[5][7] It is a controlled substance in Canada under phenethylamine blanket-ban language.[8]